Tigermed (03347) has announced the completion of the sale of all issued shares of Shanghai Guanhe Medical Technology Co., Ltd. All conditions outlined in the share transfer agreement have been fulfilled, and the transaction was finalized on March 3, 2026, in accordance with the terms of the agreement. Following the sale, the target company and its subsidiaries, collectively referred to as the target group, will continue to operate as subsidiaries of Tigermed. The financial results of the target group will be consolidated into the financial statements of the Fangda Group. As the transaction is an internal transfer within the group, it is not expected to have any material impact on the group's consolidated financial position.